Physician profile
Seth Adam Jarrell
NPI 1891135208
$6,400.68
in general payments reported to CMS, 2019-2025
30 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,712 · 2020: $1,458 · 2021: $796 · 2022: $1,025 · 2023: $501 · 2024: $439 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,409.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,498.12 | 2019-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $897.04 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $634.86 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $531.57 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $464.78 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $446.59 | 2019-2023 | Jardiance |
| Amgen INC. | $316.75 | 2019-2024 | Otezla, Repatha |
| Amarin Pharma, INC. | $228.75 | 2019-2021 | |
| Exact Sciences Corporation | $218.06 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $172.18 | 2022-2025 | |
| Abbvie INC. | $145.77 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.44 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $92.22 | 2019-2025 | Capvaxive |
| Janssen Pharmaceuticals, INC | $85.76 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $83.74 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $56.41 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $50.11 | 2019-2021 | |
| Corcept Therapeutics | $49.09 | 2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $42.52 | 2019-2020 | |
| Shield Therapeutics INC | $41.27 | 2023-2025 | Accrufer |
| Bausch Health US, LLC | $38.21 | 2024-2025 | Wellbutrin, Aplenzin |
| Mylan Specialty L.P. | $36.76 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $34.39 | 2020-2021 | |
| Vivus LLC | $23.54 | 2022 | |
| Genentech USA, INC. | $22.11 | 2021 | |
| Inspire Medical Systems, INC. | $18.09 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $17.78 | 2019 | |
| Currax Pharmaceuticals LLC | $15.36 | 2022 | |
| Eisai INC. | $14.10 | 2020 | |
| Allergan, INC. | $12.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Jarrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.